Characteristics and Risk Factor Burden of Patients Receiving Lipid Modifying Therapy in the United Kingdom

Trial Profile

Characteristics and Risk Factor Burden of Patients Receiving Lipid Modifying Therapy in the United Kingdom

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 23 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top